Screening Epidemiological Program on Compensation Evaluation of Diabetes Mellitus Type 2 (DMT2) Patients on Oral Anti-diabetic (OAD) Monotherapy and Physicians Satisfaction of Their Usage

NCT01275794 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 1849

Last updated 2012-06-04

No results posted yet for this study

Summary

The purpose of the study is assessment of glycemic control and physicians satisfaction with results of DM2 OAD monotherapy

Conditions

Sponsors & Collaborators

Principal Investigators

  • Alexey Stepanov · AstraZeneca

Eligibility

Min Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-12-31
Primary Completion
2011-03-31
Completion
2011-03-31

Countries

  • Russia

Study Locations

More Related Trials

Entities

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01275794 on ClinicalTrials.gov